Andere talen Kymera Therapeutics, Inc.

Aandelen

KYMR

US5015751044

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 18-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
35,12 ^USD	+4,03%		-5,62%	+37,94%

08/04	Kymera Therapeutics, Inc. kondigt wetenschappelijke presentaties aan op de jaarlijkse bijeenkomst van de American Association for Cancer Research 2024	CI
01/04	Kymera Therapeutics, Inc. Benoemt Felix J. Baker tot lid van de Raad van Bestuur	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Kymera Therapeutics Announces Scientific Presentations at the American Association for Cancer Research 2024 Annual Meeting	08/04
Kymera Therapeutics Announces Scientific Presentations at the American Association for Cancer Research 2024 Annual Meeting	08/04
Kymera Therapeutics, Inc Announces Scientific Presentations At the American Association for Cancer Research 2024 Annual Meeting	08/04
Kymera Therapeutics, Inc. Appoints Felix J. Baker to the Board	01/04
Kymera Therapeutics Insider Sold Shares Worth $14,912,376, According to a Recent SEC Filing	14/03
Kymera Therapeutics Presents Preclinical Data for STAT6 and TYK2 First-In-Class, Oral Degrader Immunology Programs at the American Academy of Dermatology Annual Meeting	11/03
Kymera Therapeutics Presents Preclinical Data for STAT6 and TYK2 First-In-Class, Oral Degrader Immunology Programs at the American Academy of Dermatology Annual Meeting	08/03
Kymera Therapeutics Presents Preclinical Data for STAT6 and TYK2 First-In-Class, Oral Degrader Immunology Programs At the American Academy of Dermatology Annual Meeting	08/03
Kymera Therapeutics to Participate in Upcoming March Investor Conferences	28/02
Kymera Therapeutics to Participate in Upcoming March Investor Conferences	28/02
Kymera Therapeutics Q4 Net Loss Narrows, Collaboration Revenue Rises	22/02
Kymera Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	22/02
Kymera Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	22/02
Kymera Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update	22/02
Kymera Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update	22/02
Kymera Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on February 22	15/02
Kymera Therapeutics to Present in Fireside Chat at the Guggenheim Healthcare Conference	31/01
Kymera Therapeutics Insider Sold Shares Worth $300,470, According to a Recent SEC Filing	24/01
Kymera Therapeutics Raises $316.2 Million From Offering, Outlines Cash Runway Guidance	09/01
Kymera Therapeutics Outlines Key 2024 Objectives and Strategy to Progress Leading Portfolio of Immunology and Oncology Programs	09/01

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Kymera Therapeutics, Inc.

Aandelen

KYMR

US5015751044

Andere talen

Filters